Axovant Sciences (NASDAQ:AXON)‘s stock had its “buy” rating restated by investment analysts at HC Wainwright in a report released on Friday. They currently have a $11.00 target price on the biotechnology company’s stock. HC Wainwright’s price target would suggest a potential upside of 105.80% from the company’s previous close.

AXON has been the subject of several other research reports. BidaskClub lowered Axovant Sciences from a “sell” rating to a “strong sell” rating in a research report on Friday, September 15th. Jefferies Group set a $40.00 price objective on Axovant Sciences and gave the stock a “buy” rating in a report on Friday, August 25th. Oppenheimer reiterated a “buy” rating and issued a $30.00 price objective on shares of Axovant Sciences in a report on Monday, September 25th. Evercore ISI restated an “outperform” rating and set a $9.00 price target (down from $30.00) on shares of Axovant Sciences in a research note on Tuesday, September 26th. Finally, ValuEngine downgraded Axovant Sciences from a “hold” rating to a “sell” rating in a research note on Tuesday, September 26th. Three equities research analysts have rated the stock with a sell rating, six have assigned a hold rating and six have assigned a buy rating to the stock. The company has a consensus rating of “Hold” and an average target price of $14.13.

Shares of Axovant Sciences (AXON) traded down $0.17 during trading on Friday, reaching $5.35. The company’s stock had a trading volume of 523,375 shares, compared to its average volume of 1,019,414. The company has a quick ratio of 5.94, a current ratio of 5.94 and a debt-to-equity ratio of 0.34. Axovant Sciences has a fifty-two week low of $4.60 and a fifty-two week high of $27.98.

Hedge funds and other institutional investors have recently bought and sold shares of the stock. FMR LLC raised its holdings in shares of Axovant Sciences by 968.5% during the 2nd quarter. FMR LLC now owns 7,235,632 shares of the biotechnology company’s stock worth $167,794,000 after acquiring an additional 6,558,462 shares in the last quarter. Janus Henderson Group PLC purchased a new stake in shares of Axovant Sciences during the 2nd quarter worth approximately $47,854,000. OxFORD Asset Management LLP increased its position in shares of Axovant Sciences by 842.1% during the 3rd quarter. OxFORD Asset Management LLP now owns 869,834 shares of the biotechnology company’s stock valued at $5,838,000 after purchasing an additional 777,505 shares during the last quarter. Capital Research Global Investors increased its position in shares of Axovant Sciences by 21.8% during the 2nd quarter. Capital Research Global Investors now owns 3,453,800 shares of the biotechnology company’s stock valued at $80,094,000 after purchasing an additional 619,226 shares during the last quarter. Finally, Eagle Asset Management Inc. bought a new position in shares of Axovant Sciences during the 3rd quarter valued at approximately $4,471,000. 96.93% of the stock is currently owned by institutional investors.

COPYRIGHT VIOLATION NOTICE: This article was originally published by Daily Political and is the property of of Daily Political. If you are reading this article on another publication, it was illegally stolen and republished in violation of United States & international copyright and trademark law. The correct version of this article can be read at https://www.dailypolitical.com/2017/12/01/hc-wainwright-reaffirms-buy-rating-for-axovant-sciences-axon.html.

Axovant Sciences Company Profile

Axovant Sciences Ltd. is a clinical-stage biopharmaceutical company. The Company is focused on acquiring, developing and commercializing therapeutics for the treatment of dementia, including Alzheimer’s disease and Lewy body dementia. The Company intends to develop a pipeline of product candidates to address the cognitive, functional and behavioral aspects of dementia and related neurological disorders.

Analyst Recommendations for Axovant Sciences (NASDAQ:AXON)

Receive News & Ratings for Axovant Sciences Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Axovant Sciences Ltd. and related companies with MarketBeat.com's FREE daily email newsletter.